Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ADN016
MIFTS: 63

Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Adenocarcinoma

About this section

MalaCards integrated aliases for Adenocarcinoma:

Name: Adenocarcinoma 12 54 6 44 15 17 71
Adenocarcinomas 15

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Endocrine diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:299
MeSH 44 D000230
NCIt 50 C2852
SNOMED-CT 67 443961001
UMLS 71 C0001418
Sources

Summaries for Adenocarcinoma

About this section
Disease Ontology : 12 A carcinoma that has material basis in abnormally proliferating cells, derives from epithelial cells, which originate in glandular tissue.

MalaCards based summary : Adenocarcinoma, also known as adenocarcinomas, is related to barrett esophagus and small intestine adenocarcinoma. An important gene associated with Adenocarcinoma is HNF1A-AS1 (HNF1A Antisense RNA 1), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Iron isomaltoside 1000 and Lidocaine have been mentioned in the context of this disorder. Affiliated tissues include prostate, colon and pancreas, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Adenocarcinoma (/ˌædɪnoʊkɑːrsɪˈnoʊmə/; plural adenocarcinomas or adenocarcinomata... more...

Sources

Related Diseases for Adenocarcinoma

About this section

Diseases in the Adenocarcinoma family:

Adenocarcinoma in Situ

Diseases related to Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2396)
# Related Disease Score Top Affiliating Genes
1 barrett esophagus 33.3 TP53 SMAD4 ERBB2 CTNNB1 CDKN2A APC
2 small intestine adenocarcinoma 33.2 MLH1 KRAS HRAS CTNNB1
3 endometrial adenocarcinoma 33.2 TP53 MLH1 KRAS ERBB2 EGFR CTNNB1
4 mucinous adenocarcinoma 33.2 TP53 MLH1 KRAS ERBB2 EGFR CDKN2A
5 pancreatic adenocarcinoma 33.2 TP53 TGFBR2 SMAD4 PIK3CA KRAS HRAS
6 clear cell adenocarcinoma 33.2 TP53 SMAD4 PIK3CA
7 appendix adenocarcinoma 33.1 KRAS HRAS
8 cervical adenocarcinoma 33.1 TP53 KRAS ERBB2 EGFR CDKN2A AKT1
9 papillary adenocarcinoma 33.1 TP53 ERBB2 CDH1
10 suppression of tumorigenicity 12 33.1 TP53 SMAD4 PIK3CA HRAS ERBB2 EGFR
11 pancreatic ductal adenocarcinoma 33.1 TP53 SMAD4 KRAS H19 ERBB2 EGFR
12 colon adenocarcinoma 33.1 TP53 SMAD4 PIK3CA MLH1 KRAS ERBB2
13 rectum adenocarcinoma 33.0 TP53 PIK3CA MLH1 KRAS HRAS ERBB2
14 tubular adenocarcinoma 33.0 ERBB2 EGFR CTNNB1 CDH1
15 bronchiolo-alveolar adenocarcinoma 33.0 KRAS HRAS EGFR CDH1
16 ovary adenocarcinoma 33.0 TP53 SMAD4 PIK3CA KRAS HRAS ERBB2
17 colorectal adenocarcinoma 33.0 TP53 MLH1 KRAS HRAS ERBB2 EGFR
18 gastric adenocarcinoma 32.9 TP53 SMAD4 PIK3CA MLH1 KRAS HRAS
19 signet ring cell adenocarcinoma 32.9 TP53 MLH1 KRAS HRAS ERBB2 CTNNB1
20 barrett's adenocarcinoma 32.9 TP53 KRAS ERBB2 CDKN2A
21 scirrhous adenocarcinoma 32.8 ERBB2 CDH1
22 breast adenocarcinoma 32.8 TP53 RB1 PIK3CA KRAS H19 ERBB2
23 lung cancer susceptibility 3 32.8 TP53 TGFBR2 SMAD4 RB1 PIK3CA MLH1
24 gallbladder adenocarcinoma 32.8 TP53 PIK3CA ERBB2 EGFR
25 gastric papillary adenocarcinoma 32.8 TP53 ERBB2
26 adenosquamous carcinoma 32.8 TP53 SMAD4 PIK3CA KRAS EGFR
27 duodenum adenocarcinoma 32.8 MLH1 KRAS HRAS
28 gastric cancer, hereditary diffuse 32.7 TP53 SMAD4 MLH1 KRAS EPCAM CTNNB1
29 endocervical adenocarcinoma 32.7 TP53 PIK3CA ERBB2 CDKN2A
30 ethmoid sinus adenocarcinoma 32.7 PIK3CA KRAS HRAS ERBB2 EGFR
31 papillary serous adenocarcinoma 32.7 TP53 KRAS HRAS
32 sebaceous adenocarcinoma 32.7 TP53 MLH1 ERBB2
33 nasal cavity adenocarcinoma 32.6 TP53 KRAS HRAS CDKN2A
34 urachal adenocarcinoma 32.6 KRAS BRAF
35 serous cystadenocarcinoma 32.6 TP53 PIK3CA KRAS HRAS ERBB2 BRAF
36 endometrial serous adenocarcinoma 32.6 TP53 PIK3CA KRAS ERBB2
37 esophageal cancer 32.6 TP53 TGFBR2 SMAD4 RB1 PIK3CA MLH1
38 thyroid gland follicular carcinoma 32.6 TP53 PIK3CA KRAS HRAS ERBB2 EGFR
39 adenoid cystic carcinoma 32.5 TP53 PIK3CA KRAS HRAS ERBB2 EGFR
40 large intestine adenocarcinoma 32.5 TP53 SMAD4 PIK3CA KRAS HRAS ERBB2
41 vulvar adenocarcinoma 32.5 TP53 RB1
42 renal cell carcinoma, papillary, 1 32.5 TP53 PIK3CA HRAS ERBB2 EGFR CTNNB1
43 renal cell carcinoma, nonpapillary 32.5 TP53 PIK3CA HRAS H19 EPCAM EGFR
44 bile duct adenocarcinoma 32.5 TP53 KRAS HRAS ERBB2 EPCAM EGFR
45 merkel cell carcinoma 32.4 TP53 RB1 CTNNB1 CDKN2A
46 wolffian duct adenocarcinoma 32.4 KRAS HRAS
47 mucinous lung adenocarcinoma 32.4 KRAS HRAS
48 pulmonary adenocarcinoma in situ 32.4 KRAS HRAS EGFR AKT1
49 epithelial-myoepithelial carcinoma 32.4 TP53 PIK3CA HRAS AKT1
50 adenosquamous lung carcinoma 32.3 PIK3CA KRAS HRAS EGFR

Graphical network of the top 20 diseases related to Adenocarcinoma:



Diseases related to Adenocarcinoma
Sources

Symptoms & Phenotypes for Adenocarcinoma

About this section

GenomeRNAi Phenotypes related to Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show all 45)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 11.1 BRAF KRAS HRAS EGFR PIK3CA
2 Decreased viability GR00055-A-2 11.1 BRAF KRAS HRAS EGFR PIK3CA
3 Decreased viability GR00055-A-3 11.1 KRAS
4 Decreased viability GR00106-A-0 11.1 KRAS
5 Decreased viability GR00107-A-1 11.1 TGFBR2
6 Decreased viability GR00221-A-1 11.1 CDH1 KRAS AKT1 CDKN2A HRAS TGFBR2
7 Decreased viability GR00221-A-2 11.1 KRAS AKT1 HRAS PIK3CA
8 Decreased viability GR00221-A-3 11.1 AKT1 CDKN2A ERBB2 HRAS TGFBR2
9 Decreased viability GR00221-A-4 11.1 BRAF AKT1 CDKN2A ERBB2 TGFBR2 EGFR
10 Decreased viability GR00249-S 11.1 BRAF AKT1 TGFBR2
11 Decreased viability GR00301-A 11.1 BRAF CDH1 ERBB4 KRAS
12 Decreased viability GR00342-S-1 11.1 ERBB4
13 Decreased viability GR00381-A-1 11.1 BRAF KRAS
14 Decreased viability GR00402-S-2 11.1 CDH1 TGFBR2 PIK3CA
15 Increased shRNA abundance (Z-score > 2) GR00366-A-1 10.2 MLH1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-107 10.2 SMAD4
17 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.2 SMAD4
18 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.2 KRAS
19 Increased shRNA abundance (Z-score > 2) GR00366-A-124 10.2 MLH1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-133 10.2 APC
21 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.2 BRAF
22 Increased shRNA abundance (Z-score > 2) GR00366-A-172 10.2 RB1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.2 RB1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-181 10.2 RB1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-192 10.2 APC
26 Increased shRNA abundance (Z-score > 2) GR00366-A-195 10.2 MLH1 SMAD4
27 Increased shRNA abundance (Z-score > 2) GR00366-A-200 10.2 MLH1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-202 10.2 APC
29 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.2 RB1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-212 10.2 SMAD4
31 Increased shRNA abundance (Z-score > 2) GR00366-A-213 10.2 AKT1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-22 10.2 KRAS
33 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.2 SMAD4
34 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.2 SMAD4 RB1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.2 CTNNB1 BRAF
36 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.2 RB1
37 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10.2 AKT1 PIK3CA
38 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.2 KRAS
39 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.2 AKT1
40 Increased shRNA abundance (Z-score > 2) GR00366-A-78 10.2 MLH1
41 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.2 AKT1
42 Decreased cell migration GR00055-A-1 9.97 AKT1
43 Decreased cell migration GR00055-A-3 9.97 BRAF EGFR HRAS PIK3CA
44 Reduced mammosphere formation GR00396-S 9.17 BRAF CDH1 EGFR H19 HRAS KRAS
45 Increased focal adhesion (FA) area, decreased number of small and round FAs, increased peripheral FA formation, increased cell spreading GR00210-A 8.85 CTNNB1

MGI Mouse Phenotypes related to Adenocarcinoma:

46 (show all 28)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.56 AKT1 APC BRAF CDH1 CDKN2A CTNNB1
2 cellular MP:0005384 10.55 AKT1 APC BRAF CDH1 CDKN2A CTNNB1
3 endocrine/exocrine gland MP:0005379 10.55 AKT1 APC BRAF CDH1 CDKN2A CTNNB1
4 behavior/neurological MP:0005386 10.54 AKT1 APC BRAF CDKN2A CTNNB1 EPCAM
5 embryo MP:0005380 10.51 AKT1 APC BRAF CDH1 CDKN2A CTNNB1
6 homeostasis/metabolism MP:0005376 10.5 AKT1 APC BRAF CDH1 CDKN2A CTNNB1
7 digestive/alimentary MP:0005381 10.49 APC BRAF CDH1 CDKN2A CTNNB1 EGFR
8 growth/size/body region MP:0005378 10.49 AKT1 APC BRAF CDH1 CDKN2A CTNNB1
9 integument MP:0010771 10.48 AKT1 APC BRAF CDH1 CDKN2A CTNNB1
10 immune system MP:0005387 10.46 AKT1 APC BRAF CDH1 CDKN2A CTNNB1
11 mortality/aging MP:0010768 10.46 AKT1 APC BRAF CDH1 CDKN2A CTNNB1
12 hematopoietic system MP:0005397 10.42 AKT1 APC BRAF CDKN2A CTNNB1 EGFR
13 craniofacial MP:0005382 10.4 APC BRAF CTNNB1 EGFR ERBB2 ERBB4
14 neoplasm MP:0002006 10.38 AKT1 APC BRAF CDH1 CDKN2A CTNNB1
15 muscle MP:0005369 10.37 AKT1 APC BRAF CDKN2A CTNNB1 EGFR
16 nervous system MP:0003631 10.36 AKT1 APC BRAF CDKN2A CTNNB1 EGFR
17 liver/biliary system MP:0005370 10.26 AKT1 APC BRAF CDKN2A CTNNB1 EGFR
18 normal MP:0002873 10.25 AKT1 APC BRAF CDH1 CTNNB1 EGFR
19 adipose tissue MP:0005375 10.24 AKT1 APC BRAF EGFR PIK3CA RB1
20 limbs/digits/tail MP:0005371 10.19 APC BRAF CTNNB1 EGFR ERBB2 KRAS
21 hearing/vestibular/ear MP:0005377 10.13 APC BRAF CTNNB1 EGFR KRAS RB1
22 no phenotypic analysis MP:0003012 10.13 CDH1 CDKN2A CTNNB1 EGFR EPCAM HRAS
23 reproductive system MP:0005389 10.13 AKT1 APC BRAF CDH1 CDKN2A CTNNB1
24 pigmentation MP:0001186 10.02 APC BRAF CDKN2A CTNNB1 EGFR KRAS
25 renal/urinary system MP:0005367 10.02 APC BRAF CTNNB1 EGFR HRAS KRAS
26 respiratory system MP:0005388 9.97 AKT1 BRAF CDKN2A CTNNB1 EGFR ERBB2
27 skeleton MP:0005390 9.8 AKT1 APC BRAF CDKN2A CTNNB1 EGFR
28 vision/eye MP:0005391 9.32 APC BRAF CDKN2A CTNNB1 EGFR KRAS
Sources

Drugs & Therapeutics for Adenocarcinoma

About this section

Drugs for Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 657)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iron isomaltoside 1000 Approved, Investigational Phase 4 1370654-58-2
2
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
3
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
4
Desflurane Approved Phase 4 57041-67-5 42113
5
Prilocaine Approved Phase 4 721-50-6 4906
6
Fesoterodine Approved Phase 4 286930-03-8, 286930-02-7 6918558
7
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
8
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
9
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
10
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
11
Iron Approved Phase 4 7439-89-6 23925 29936
12
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
13
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
14 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
15
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
16
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
17
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
18
Gefitinib Approved, Investigational Phase 4 184475-35-2 123631
19
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
20
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
21 Endostar protein Phase 4
22 Endostatins Phase 4 71581480
23 Vaccines Phase 4
24 Cholinergic Agents Phase 4
25 Sodium Channel Blockers Phase 4
26 Diuretics, Potassium Sparing Phase 4
27 Anesthetics, Inhalation Phase 4
28 Anesthetics, General Phase 4
29 Cholinergic Antagonists Phase 4
30 Muscarinic Antagonists Phase 4
31 Adrenergic alpha-Agonists Phase 4
32 Excitatory Amino Acid Antagonists Phase 4
33 Anesthetics, Intravenous Phase 4
34 Anesthetics, Dissociative Phase 4
35 Adrenergic Agonists Phase 4
36 Hepcidins Phase 4
37 Methylprednisolone Acetate Phase 4
38 Anti-Inflammatory Agents Phase 4
39 Antineoplastic Agents, Hormonal Phase 4
40 glucocorticoids Phase 4
41
Trioxsalen Approved Phase 3 3902-71-4 5585
42
Darbepoetin alfa Approved, Investigational Phase 2, Phase 3 209810-58-2, 11096-26-7
43
Hydroxyurea Approved Phase 3 127-07-1 3657
44
Midazolam Approved, Illicit Phase 3 59467-70-8 4192
45
Zoledronic Acid Approved Phase 3 118072-93-8 68740
46
Norepinephrine Approved Phase 3 51-41-2 439260
47
Cyproterone Acetate Approved, Investigational Phase 3 427-51-0
48
Estramustine Approved, Investigational Phase 3 2998-57-4 18140 259331
49
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
50
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754

Interventional clinical trials:

(show top 50) (show all 2751)
# Name Status NCT ID Phase Drugs
1 A Randomized ,Opened, Prospective Controlled Trial of Clinical Effectiveness for Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With Epidermal Growth Factor Receptor Gene Mutation Unknown status NCT02283424 Phase 4 Icotinib;chemotherapy (Carboplatin and Docetaxel)
2 Recombinant Human Endostatin Durative Transfusion Combined With Pemetrexed Plus Cisplatin or Carboplatin in the First-line Treatment of Advanced Lung Adenocarcinoma With Wild-type EGFR or ALK-negative Unknown status NCT02804646 Phase 4 recombinant human endostatin;pemetrexed plus cisplatin or carboplatin
3 Comparative Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma Unknown status NCT02399566 Phase 4 Erlotinib, Pemetrexed
4 Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma: a Randomized, Open-label, Multicenter Study Unknown status NCT02103257 Phase 4 Sequential Icotinib Plus Chemotherapy;Icotinib
5 Randomized, Open Label, Positive Controlled, Multicenter Trial to Evaluate Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma Unknown status NCT01665417 Phase 4 Experimental;Chemotherapy;Chemotherapy
6 The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer Unknown status NCT03401827 Phase 4 Chemotherapy (Gemcitabine + nab-paclitaxel)
7 An Pilot Study to Assess the Efficacy of Intravenous Iron Isomaltoside 1000 (Monofer®) in the Management of Anaemia Associated With the Palliative Management of Oesophagogastric Adenocarcinoma Unknown status NCT01927328 Phase 4 Iron isomaltoside 1000
8 An Open Label, Single Group Assigned, Multicenter Study of Apatinib in Patients With Chemo-refractory Advanced or Metastatic Adenocarcinoma of Stomach or Gastroesophageal Junction Unknown status NCT02426034 Phase 4 Apatinib
9 Endoscopic Detection of Small Bowel Dysplasia and Cancer in Patients With Jejuna or Ileal Crohn Disease : Prospective Study in a Cohort of High Risk Patients Completed NCT01180452 Phase 4
10 Early Assessment of the Response to Neo-adjuvant Chemotherapy in Breast Cancer Patients With FDG-PET Completed NCT00904410 Phase 4
11 Open Label Study of Erlotinib (Tarceva®) as Single Agent First Line Treatment of Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With Activating Epidermal Growth Factor Receptor (EGFR) Mutations Completed NCT01609543 Phase 4 erlotinib [Tarceva]
12 Resectable Pancreatic Adenocarcinoma - Does the Type of Anesthesia Have an Impact on Circulating Tumor Cells? Completed NCT02335151 Phase 4 Desflurane
13 A Pharmacokinetic Study of Adjuvant Capecitabine in Patients Who Have Undergone Proximal Pancreatico-duodenectomy for Resection of Pancreatic Adenocarcinoma Completed NCT00854477 Phase 4 capecitabine
14 Impact of Local Anesthesia Type on Cancer Detection Rate in Transrectal Ultrasound Guided Prostate Biopsy Completed NCT02025361 Phase 4 intrarectal lidocaine gel;periprostatic nerve blockade
15 A Phase IV, Randomized, Double-Blind, Placebo-Controlled, Single-Center Study of the Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Laparoscopic Prostatectomy ) Completed NCT01661166 Phase 4 Fesoterodine;Placebo oral tablet
16 Effects of Local Wound Infiltration With Ketamine Versus Dexmedetomidine Added to Bupivacaine on Inflammatory Cytokines Response After Total Abdominal Hysterectomy Completed NCT03164590 Phase 4 Ketamine;dexmedetomidine;bupivacaine
17 Effects of Preoperative Administration of Oral Rabeprazole on the Prevention of Ulcer Bleeding Following Endoscopic Mucosal Resection(EMR): Prospective, Randomized, Placebo-controlled, Comparative Study Completed NCT00844675 Phase 4 rabeprazole;placebo
18 An Open Label Study of Intravenous Iron (FERINJECT) in Colorectal Adenocarcinoma Related Anaemia to Identify Potential Biomarkers of Responsiveness to Intravenous Iron Completed NCT02057471 Phase 4 Intravenous ferric carboxymaltose
19 Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN) With Alcohol in Patients With Locally Advanced and Unresectable Pancreatic Adenocarcinoma: A Randomized Pilot Study Completed NCT00578279 Phase 4 dehydrated alcohol
20 Clinical Outcomes of Endoscopic Resection for Treating Extremely Well Differentiated Intestinal-type Adenocarcinoma (WHYX Lesion) Completed NCT01451034 Phase 4
21 Safety and Efficacy of Nab-paclitaxel (Abraxane) in Combination With Carboplatin as First Line Treatment in Elderly Subjects With Advance Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (Abound.70+) Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin
22 A Phase IV Open-Label, Descriptive Study to Evaluate the Safety and Effectiveness on the Incidence of HPV 6, 11, 16 and 18 Related CIN 2/3 or Worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in 16- to 26-Year-Old Japanese Women Completed NCT01544478 Phase 4
23 PERIOP-FOLFIRINOX: A Pilot Trial of Perioperative Genotype-guided Irinotecan Dosing of gFOLFIRINOX for Locally Advanced Gastroesophageal Adenocarcinoma Recruiting NCT02366819 Phase 4 Oxaliplatin;Leucovorin Calcium;Irinotecan Hydrochloride;Fluorouracil
24 Mechanical Bowel Preparation and Oral Antibiotics Versus Mechanical Bowel Preparation Only Prior Rectal Surgery - a Prospective, Randomized Controlled Trial Recruiting NCT04281667 Phase 4 Oral Antibiotics;Placebo;Mechanical Bowel Preparation
25 PAXG Out in the Country Recruiting NCT04480268 Phase 4 PAXG regimen (cisplatin, nab-paclitaxel, capecitabine, gemcitabine) chemotherapy
26 A Multicenter Phase 4 Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer Patients Active, not recruiting NCT02812992 Phase 4 Nab-paclitaxel;Gemcitabine
27 A Dose Escalation Safety Study of Locally-Delivered (Intra-Arterial) Gemcitabine in Unresectable Adenocarcinoma of the Pancreas Active, not recruiting NCT02237157 Phase 4 Gemcitabine, local delivery
28 Reduction in Symptomatic Oesophageal Stricture Formation Post-two Stage Complete Barrett's Excision for High Grade Dysplasia or Early Adenocarcinoma With Short-term Steroid Therapy: A Randomized, Doubleblind, Placebo-controlled, Multicentre Trial. Not yet recruiting NCT02004782 Phase 4 Prednisolone;Placebo Oral Tablet
29 A Pharmacokinetic Study of Capecitabine in Patients Undergoing Peri-operative Chemotherapy and a Total Gastrectomy for Adenocarcinoma of the Stomach Terminated NCT00871273 Phase 4 capecitabine
30 Reduction in Symptomatic Esophageal Stricture Formation Post-two Stage Complete Barrett's Excision for High Grade Dysplasia or Early Adenocarcinoma With Short-term Steroid Therapy: A Randomized, Double-blinded, Placebo-controlled, Multicenter Trial. Terminated NCT02039115 Phase 4 prednisone;placebo
31 A Randomized/Open Label/Parallel Group/Multicenter/Phase IV Study to Assess Safety/Tolerability/Efficacy of Oral Gefitinib 250 mg Versus IV Docetaxel 60 mg/m2 in Patients With Locally Advanced or Metastatic NSCL Cancer of Adenocarcinoma Histology Previous Treated With One Platinum Base Chemotherapy Terminated NCT00536107 Phase 4 Gefitinib;Docetaxel
32 Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy Withdrawn NCT02570529 Phase 4 Albis®;Placebo
33 Exocrine Pancreatic Insufficiency in Pancreatic Cancer: Evaluating the Need and Efficacy of Pancreatic Enzyme Replacement Therapy Withdrawn NCT01401387 Phase 4
34 A Pilot Study of Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma Withdrawn NCT03891979 Phase 4 Pembrolizumab;Ciprofloxacin 500mg PO BID days 1-29;Metronidazole 500mg PO TID days 1-29
35 The Comparison of Value of Brachytherapy and Endoscopic Stenting With SEMS in Palliative Treatment of Dysphagia Resulting From Adenocarcinoma of the Esophago-Gastric Junction Unknown status NCT01786278 Phase 2, Phase 3
36 A Randomised Phase II/III Trial of Peri-Operative Chemotherapy With or Without Bevacizumab in Operable Oesophagogastric Adenocarcinoma and A Feasibility Study Evaluating Lapatinib in HER-2 Positive Oesophagogastric Adenocarcinomas and (in Selected Centres) MRI and PET/CT Sub-studies Unknown status NCT00450203 Phase 2, Phase 3 capecitabine;cisplatin;Epirubicin;Lapatinib
37 Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? Unknown status NCT00719303 Phase 3
38 Pemetrexed Disodium and Cisplatin Chemotherapy Combined With Synchronous Gefitinib vs Chemotherapy Alone as Adjuvent Therapy in Patient With Stage II-IIIA, Epidermal Growth Factor Receptor Mutant Expressing Lung Adenocarcinoma Unknown status NCT02518802 Phase 3 Gefitinib;Pemetrexed
39 A Multi-center Phase III Randomized Controlled Trial Comparing Between Adjuvant Chemotherapy and Observation in High Risk Patients With Completely Resected Stage Ib Lung Adenocarcinoma Unknown status NCT02281708 Phase 3 vinorelbine plus cisplatin
40 Efficacy and Safety Study of the Combined Modality Therapy in Patients With Potentially Resectable, Locally Advanced Adenocarcinoma of the Esophago-gastric Junction With Preoperative Chemo- and Chemoradiation Followed by Surgical Resection Unknown status NCT01523015 Phase 2, Phase 3
41 A Pilot Randomized Controlled Trial Examining the Differences of Quality of Life of Patients Undergoing Total Gastrectomy or Proximal Gastrectomy for Adenocarcinoma of Esophagogastric Junction Unknown status NCT01697917 Phase 3
42 Phase Ⅱ/Ⅲ Study of Preoperative Concurrent Chemoradiotherapy for Locally Advanced Gastroesophageal Junction or Upper Gastric Adenocarcinoma Unknown status NCT02193594 Phase 2, Phase 3 Adjuvant chemotherapy
43 Use of the Eus-guided Cryothermal Ablation in the Multimodality Approach to Patients With Stage III (Locally Advanced and Borderline Resectable) Pancreatic Adenocarcinoma Unknown status NCT03649035 Phase 3
44 A Randomized, Multicenter, Open-label, Phase III Trial of Docetaxel and S1 (DS) Versus S1 and Cisplatin (SP) in Curatively Resected (D2) Gastric Cancer of Stage IIIB/IV (M0) Unknown status NCT01283217 Phase 3 DS;SP
45 A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial Unknown status NCT01414608 Phase 3 Carboplatin;Cisplatin;Paclitaxel
46 Two-arm Phase III Trial Comparing Different Time of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer Unknown status NCT02628665 Phase 3 photosensitizer(photofrin)
47 Non-Metastatic High-Risk Prostate Cancer Patients With Biochemical Relapse Only After Local Treatment. A Prospective Randomized Phase III Study Comparing Hormonal Therapy +/-Docetaxel Unknown status NCT00764166 Phase 3 Docetaxel + hormonal treatment (LH-RH agonist);Hormonal treatment (LH-RH agonist)
48 A Phase III Study of Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2 Lymphadenectomy Unknown status NCT02240524 Phase 3
49 A Prospective, Randomized, One-center Study Comparing Hepatic Arterial Infusion Plus Chemotherapy ± Target Therapy and Chemotherapy ± Target Therapy Alone in Patients With Unresectable Colorectal Cancer Liver Metastases Unknown status NCT03125161 Phase 3 HAI;chemotherapy ± target therapy
50 A Novel 18F-DCFPyL PET-CT Scan for Diagnosis and Management of Prostate Cancer Unknown status NCT03852654 Phase 2, Phase 3 18F-DCFPyL

Search NIH Clinical Center for Adenocarcinoma

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Thiotepa

Cochrane evidence based reviews: adenocarcinoma

Sources

Genetic Tests for Adenocarcinoma

About this section
Sources

Anatomical Context for Adenocarcinoma

About this section

MalaCards organs/tissues related to Adenocarcinoma:

40
Prostate, Colon, Pancreas, Lung, Lymph Node, Thyroid, Cervix
Sources

Publications for Adenocarcinoma

About this section

Articles related to Adenocarcinoma:

(show top 50) (show all 57368)
# Title Authors PMID Year
1
Expression of RACK1 is a novel biomarker in pulmonary adenocarcinomas. 61 54
19892429 2010
2
Role of CDK8 and beta-catenin in colorectal adenocarcinoma. 54 61
20514474 2010
3
Expression of the chemokine receptor CXCR4 correlates with a favorable prognosis in patients with adenocarcinoma of the lung. 61 54
19716197 2010
4
Clinical significance of ephrin (eph)-A1, -A2, -a4, -a5 and -a7 receptors in pancreatic ductal adenocarcinoma. 54 61
19949912 2010
5
The impact of expressions of CD97 and its ligand CD55 at the invasion front on prognosis of rectal adenocarcinoma. 54 61
20339853 2010
6
ZM336372 induces apoptosis associated with phosphorylation of GSK-3beta in pancreatic adenocarcinoma cell lines. 61 54
20031160 2010
7
A novel clinically relevant animal model for studying galectin-3 and its ligands during colon carcinogenesis. 61 54
20197492 2010
8
Overexpression of FADD enhances 5-fluorouracil-induced apoptosis in colorectal adenocarcinoma cells. 61 54
19415536 2010
9
Gene amplification of ERBB2 and EGFR in adenocarcinoma in situ and intramucosal adenocarcinoma of Barrett's esophagus. 54 61
20518902 2010
10
HIF-1 alpha signaling is augmented during intermittent hypoxia by induction of the Nrf2 pathway in NOX1-expressing adenocarcinoma A549 cells. 54 61
20347035 2010
11
Immunohistochemical expression of estrogens and progesterone receptors in carcinoma ex pleomorphic adenoma-undifferentiated and adenocarcinoma types. 61 54
20038908 2010
12
True cytokeratin 8/18 immunohistochemistry is of no use in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study. 61 54
20407331 2010
13
Utility of thyroid transcription factor-1 and CDX-2 in determining the primary site of metastatic adenocarcinomas in serous effusions. 54 61
20518411 2010
14
MUC16 expression and risk of adenocarcinoma metastases to peritoneum, pleura, leptomeninges, and brain. 61 54
20090516 2010
15
DNA damage detected with gammaH2AX in endometrioid adenocarcinoma cell lines. 61 54
20372780 2010
16
The diagnostic utility of immunohistochemistry in distinguishing primary skin adnexal carcinomas from metastatic adenocarcinoma to skin: an immunohistochemical reappraisal using cytokeratin 15, nestin, p63, D2-40, and calretinin. 54 61
20190734 2010
17
Temporal proteomic analysis of IGF-1R signalling in MCF-7 breast adenocarcinoma cells. 61 54
20213678 2010
18
Could recombinant insulin compounds contribute to adenocarcinoma progression by stimulating local angiogenesis? 61 54
20182859 2010
19
Genetic evolution of epidermal growth factor receptor in adenocarcinoma with a bronchioloalveolar carcinoma component. 61 54
20439191 2010
20
Immunohistochemical characterization of pyrimidine synthetic enzymes, thymidine kinase-1 and thymidylate synthase, in various types of cancer. 61 54
20372850 2010
21
A study of immunohistochemical differential expression in pulmonary and mammary carcinomas. 61 54
20173733 2010
22
Identification of gastrointestinal contamination in endoscopic ultrasound-guided pancreatic fine needle aspiration. 54 61
20518405 2010
23
The significance of galectin-3 immunohistochemistry, clinical characteristics and liver imaging in differentiating intrahepatic cholangiocarcinoma from adenocarcinoma liver metastasis. 61 54
20524437 2010
24
Combination of MUC5ac and WT-1 immunohistochemistry is useful in distinguishing pancreatic ductal carcinoma from ovarian serous carcinoma in effusion cytology. 61 54
19856421 2010
25
Immunohistochemical detection of receptor tyrosine kinases c-kit, EGF-R, and PDGF-R in colorectal adenocarcinomas. 61 54
19280218 2010
26
Lymph node involvement and not the histophatologic subtype is correlated with outcome after resection of adenocarcinoma of the ampulla of vater. 61 54
20107918 2010
27
Microcystic adenocarcinoma of the prostate: a variant of pseudohyperplastic and atrophic patterns. 54 61
20216381 2010
28
Cyclin D1 immunoreactivity in normal endocervix and diagnostic value in reactive and neoplastic endocervical lesions. 61 54
20062011 2010
29
Differential cell cycle and proliferation marker expression in ductal pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia (PanIN). 61 54
20350215 2010
30
Diagnostic value and implications of vimentin expression in normal, reactive and neoplastic endocervical epithelium. 61 54
20350213 2010
31
Epidermal growth factor receptor and HER-2/neu status by immunohistochemistry and fluorescence in situ hybridization in adenocarcinomas of the biliary tree and gallbladder. 54 61
20040392 2010
32
Notch-1 stimulates survival of lung adenocarcinoma cells during hypoxia by activating the IGF-1R pathway. 61 54
20154720 2010
33
Thyroid transcription factor 1 expression in ovarian carcinomas is an independent prognostic factor. 54 61
20004952 2010
34
Podoplanin is a useful marker for identifying mesothelioma in malignant effusions. 61 54
20146302 2010
35
Value of p63 and podoplanin (D2-40) immunoreactivity in the distinction between primary cutaneous tumors and adenocarcinomas metastatic to the skin: a clinicopathologic and immunohistochemical study of 79 cases. 54 61
20377670 2010
36
Immunohistochemical expression of estrogen receptor in adenocarcinomas of the lung: the antibody factor. 61 54
19875957 2010
37
Polymorphisms in promoter region of FAS and FASL gene and risk of cardia gastric adenocarcinoma. 54 61
20074157 2010
38
Stepwise progression of pulmonary adenocarcinoma--clinical and molecular implications. 54 61
20108111 2010
39
Expression of Ezrin and phosphorylated Ezrin (pEzrin) in pancreatic ductal adenocarcinoma. 61 54
20158339 2010
40
Tumor expression of integrin-linked kinase (ILK) correlates with the expression of the E-cadherin repressor snail: an immunohistochemical study in ductal pancreatic adenocarcinoma. 61 54
20091050 2010
41
Are there imaging characteristics associated with epidermal growth factor receptor and KRAS mutations in patients with adenocarcinoma of the lung with bronchioloalveolar features? 54 61
20087229 2010
42
SPARC mRNA expression as a prognostic marker for pancreatic adenocarcinoma patients. 54 61
20393008 2010
43
Quantified gene expression levels for phase I/II metabolizing enzyme and estrogen receptor levels in benign prostate from cohorts designated as high-risk (UK) versus low-risk (India) for adenocarcinoma at this organ site: a preliminary study. 61 54
19935673 2010
44
Comparison of osteopontin, beta-catenin and hnRNP B1 expression in lung carcinomas. 61 54
19609729 2010
45
Correlation between thymidylate synthase gene variants, RNA and protein levels in primary colorectal adenocarcinomas. 54 61
20515563 2010
46
CK7, CK20, CDX2 and MUC2 Immunohistochemical staining used to distinguish metastatic colorectal carcinoma involving ovary from primary ovarian mucinous adenocarcinoma. 61 54
19926591 2010
47
Dietary, lifestyle and clinicopathological factors associated with BRAF and K-ras mutations arising in distinct subsets of colorectal cancers in the EPIC Norfolk study. 61 54
20233436 2010
48
Integration of biomarkers including molecular targeted therapies in head and neck cancer. 61 54
20237991 2010
49
Significance of mucin expression in pancreatobiliary neoplasms. 54 61
19787286 2010
50
Simultaneous down-regulation of tumor suppressor genes RBSP3/CTDSPL, NPRL2/G21 and RASSF1A in primary non-small cell lung cancer. 61 54
20193080 2010
Sources

Variations for Adenocarcinoma

About this section

ClinVar genetic disease variations for Adenocarcinoma:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 TP53 NM_000546.6(TP53):c.733G>A (p.Gly245Ser) SNV Likely pathogenic 12365 rs28934575 17:7577548-7577548 17:7674230-7674230

Copy number variations for Adenocarcinoma from CNVD:

7 (show all 49)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 25149 1 184907591 184916179 Amplification PTGS2 Adenocarcinoma
2 33704 1 47467454 47552406 Amplification STIL Adenocarcinoma
3 66093 12 25249446 25295130 Amplification KRAS Adenocarcinoma
4 66576 12 3100000 5300000 Gain Adenocarcinoma
5 66578 12 3100000 5300000 Gain Adenocarcinoma
6 66580 12 3100000 5300000 Gain TSPAN9 Adenocarcinoma
7 74649 13 109973413 110012072 Amplification RAB20 Adenocarcinoma
8 87573 14 74815283 74818665 Amplification FOS Adenocarcinoma
9 93655 15 57100000 61500000 Loss RORA Adenocarcinoma
10 95696 15 79500000 83000000 Loss DNM1P41 Adenocarcinoma
11 95698 15 79500000 83000000 Loss Adenocarcinoma
12 95700 15 79500000 83000000 Loss Adenocarcinoma
13 95702 15 79500000 83000000 Loss Adenocarcinoma
14 95704 15 79500000 83000000 Loss Adenocarcinoma
15 95706 15 79500000 83000000 Loss LOC440300 Adenocarcinoma
16 95708 15 79500000 83000000 Loss Adenocarcinoma
17 97921 16 14700000 16700000 Loss Adenocarcinoma
18 107538 17 15900000 22100000 Loss Adenocarcinoma
19 111139 17 35097918 35138441 Amplification ERBB2 Adenocarcinoma
20 123836 18 89115825 89123587 Amplification SPP1 Adenocarcinoma
21 135625 2 118600000 122100000 Gain Adenocarcinoma
22 171545 3 169200000 172500000 Gain MECOM Adenocarcinoma
23 171548 3 169200000 172500000 Gain Adenocarcinoma
24 171550 3 169200000 172500000 Gain MECOM Adenocarcinoma
25 172147 3 177300000 180600000 Gain KCNMB3 Adenocarcinoma
26 172149 3 177300000 180600000 Gain PIK3CA Adenocarcinoma
27 172225 3 178866310 178952497 Gain PIK3CA Adenocarcinoma
28 172903 3 187500000 189400000 Gain MASP1 Adenocarcinoma
29 173068 3 189400000 193800000 Gain FGF12 Adenocarcinoma
30 173072 3 189400000 193800000 Gain TP63 Adenocarcinoma
31 173431 3 193800000 199501827 Gain RUBCN Adenocarcinoma
32 173434 3 193800000 199501827 Gain LOC220729 Adenocarcinoma
33 173436 3 193800000 199501827 Gain Adenocarcinoma
34 173438 3 193800000 199501827 Gain Adenocarcinoma
35 173440 3 193800000 199501827 Gain Adenocarcinoma
36 173442 3 193800000 199501827 Gain OPA1 Adenocarcinoma
37 206066 6 135544145 135582003 Amplification MYB Adenocarcinoma
38 218057 7 107200000 137300000 Amplification Adenocarcinoma
39 218695 7 116312458 116438439 Copy number MET Adenocarcinoma
40 225387 7 45400000 54000000 Copy number EGFR Adenocarcinoma
41 226106 7 55054218 55242525 Amplification EGFR Adenocarcinoma
42 230093 7 97900000 104400000 Gain TRRAP Adenocarcinoma
43 230096 7 97900000 104400000 Gain ZKSCAN1 Adenocarcinoma
44 230097 7 97900000 104400000 Gain ZNF3 Adenocarcinoma
45 230098 7 97900000 104400000 Gain ZSCAN21 Adenocarcinoma
46 233908 8 128816946 128822855 Amplification MYC Adenocarcinoma
47 239383 8 38973661 39081936 Amplification ADAM9 Adenocarcinoma
48 240761 8 55041668 55097561 Translate TCEA1 Adenocarcinoma
49 241225 8 59800000 146274826 Copy number Adenocarcinoma
Sources

Expression for Adenocarcinoma

About this section
Search GEO for disease gene expression data for Adenocarcinoma.
Sources

Pathways for Adenocarcinoma

About this section

Pathways related to Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 183)
# Super pathways Score Top Affiliating Genes
1
Signaling by GPCR 65
Show member pathways
 14.34 TP53 TGFBR2 SMAD4 PIK3CA KRAS HRAS
2
Innate Immune System 65
Show member pathways
 14.17 TP53 PIK3CA KRAS HRAS ERBB4 ERBB2
3
ERK Signaling 63
Show member pathways
 13.99 TP53 TGFBR2 SMAD4 RB1 KRAS HRAS
4
HIV Life Cycle 65
Show member pathways
 13.89 TGFBR2 SMAD4 PIK3CA KRAS HRAS ERBB4
5
GPCR Pathway 63
Show member pathways
 13.88 TP53 TGFBR2 SMAD4 RB1 KRAS HRAS
6
PEDF Induced Signaling 63
Show member pathways
 13.84 TP53 TGFBR2 SMAD4 KRAS HRAS ERBB4
7
Activation of cAMP-Dependent PKA 63
Show member pathways
 13.73 TGFBR2 SMAD4 KRAS HRAS ERBB4 ERBB2
8
TGF-Beta Pathway 63
Show member pathways
 13.73 TP53 TGFBR2 SMAD4 PIK3CA KRAS HRAS
9
Developmental Biology 65
Show member pathways
 13.68 SMAD4 PIK3CA KRAS HRAS ERBB4 ERBB2
10
Pathways of neurodegeneration - multiple diseases 36
Show member pathways
 13.62 TP53 PIK3CA KRAS HRAS ERBB4 CTNNB1
11
Class I MHC mediated antigen processing and presentation 65
Show member pathways
 13.62 TP53 PIK3CA KRAS HRAS ERBB4 ERBB2
12
Integrin Pathway 63
Show member pathways
 13.56 TGFBR2 PIK3CA KRAS HRAS EGFR CTNNB1
13
Cytokine Signaling in Immune system 65
Show member pathways
 13.54 TP53 PIK3CA KRAS HRAS ERBB4 ERBB2
14
PAK Pathway 63
Show member pathways
 13.49 TGFBR2 SMAD4 KRAS HRAS ERBB2 EGFR
15
Nanog in Mammalian ESC Pluripotency 63
Show member pathways
 13.48 KRAS HRAS ERBB4 ERBB2 EGFR CTNNB1
16
IL-2 Pathway 63
Show member pathways
 13.39 TP53 KRAS HRAS ERBB4 ERBB2 EGFR
17
TNFR1 Pathway 63
Show member pathways
 13.26 TP53 RB1 PIK3CA KRAS HRAS EGFR
18
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.26 TP53 TGFBR2 SMAD4 RB1 PIK3CA KRAS
19
GAB1 signalosome 65
Show member pathways
 13.24 TP53 PIK3CA ERBB4 ERBB2 EGFR AKT1
20
G-Beta Gamma Signaling 63
Show member pathways
 13.21 KRAS HRAS EGFR CTNNB1 CDKN2A BRAF
21
Phospholipase-C Pathway 63
Show member pathways
 13.2 TP53 KRAS HRAS EGFR BRAF AKT1
22
PI3K-Akt signaling pathway 36
Show member pathways
 13.2 TP53 RB1 PIK3CA KRAS HRAS ERBB4
23
fMLP Pathway 63
Show member pathways
 13.17 TP53 KRAS HRAS CTNNB1 CDH1 BRAF
24
Human cytomegalovirus infection 36
Show member pathways
 13.15 TP53 RB1 PIK3CA KRAS HRAS EGFR
25
Sertoli-Sertoli Cell Junction Dynamics 63
Show member pathways
 13.11 TGFBR2 KRAS HRAS CTNNB1 CDH1 BRAF
26
Regulation of lipid metabolism Insulin signaling-generic cascades 23
Show member pathways
 13.11 TGFBR2 PIK3CA KRAS HRAS ERBB2 EGFR
27
Aldosterone synthesis and secretion 36
Show member pathways
 13.11 RB1 KRAS HRAS EGFR CTNNB1 CDKN2A
28
Focal Adhesion 36 1
Show member pathways
 13.11 RB1 PIK3CA KRAS HRAS ERBB2 EGFR
29
NFAT and Cardiac Hypertrophy 63
Show member pathways
 13.08 TGFBR2 PIK3CA KRAS HRAS ERBB4 ERBB2
30
Development Angiotensin activation of ERK 23
Show member pathways
 13.02 PIK3CA KRAS HRAS EGFR BRAF AKT1
31
MAPK signaling pathway 36 1
12.99 TP53 TGFBR2 KRAS HRAS ERBB4 ERBB2
32
Ras signaling pathway 36
Show member pathways
 12.95 PIK3CA KRAS HRAS EGFR CTNNB1 CDH1
33
Downstream signaling events of B Cell Receptor (BCR) 65
Show member pathways
 12.95 TP53 PIK3CA KRAS HRAS ERBB4 ERBB2
34
Development HGF signaling pathway 23
Show member pathways
 12.94 TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
35
Beta-Adrenergic Signaling 63
Show member pathways
 12.92 KRAS HRAS CTNNB1 BRAF AKT1
36
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 64
Show member pathways